Skip to main content

Joel V. Chua, MD

Academic Title:

Associate Professor

Primary Appointment:


Administrative Title:

Chief, Surgical Infectious Diseases Service; Associate Director, Clinical Care Programs

Additional Title:

Chief, Surgical Infectious Disease, UMMC


725 West Lombard Street Baltimore, Maryland 21201

Phone (Primary):




Education and Training

Infectious Disease Fellowship, University of Maryland Medical Center, 2008-2010

Internal Medicine Residency, University of Connecticut Health Center, 2005-2008

Internal Medicine Residency, University of the Philippines - Philippine General Hospital, 2002-2004

Doctor of Medicine (M.D.), cum laude, University of the Philippines College of Medicine, 1996-2001

Bachelor of Science (B.S.), Major in Biology, magna cum laude, University of the Philippines Manila, 1992-1996 


My clinical and teaching focus in surgical infectious disease that includes care of patients with osteomyelitis, endovascular infections, ventriculitis, intraabdominal infections, empyema, and postsurgical infection. I give lectures to infectious disease fellows on intraabdominal infections, and annually invited as a faculty speaker for vascular surgeons and podiatrist on vascular infections and osteomyelitis.

My research interest and efforts involve developing novel antiviral for the treatment of neglected and emerging viruses of global importance with special interest in dengue virus infection, hepatitis B, and more recently with SARS-CoV-2. Under the mentorship of Dr. Kirsten Lyke, I am currently working on developing dengue human challenge model for the evaluation of vaccines and therapeutics as well as in search of immune correlates of protection against this virus. In addition, I am developing humanized mice model as a platform for evaluating dengue antivirals. As part of my contribution in the fight against the COVID-19 pandemic, I am actively involved in clinical trials evaluating therapeutics with expertise in the study of virus neutralizing anti-spike monoclonal antibody cocktail and antivirals as SARS-CoV-2 therapeutics.

Research/Clinical Keywords

Dengue antiviral development and immunopathogenesis, HIV vaccine clinical trials; Viral hepatitis antiviral development, and SARS-CoV-2 antiviral development.

Highlighted Publications

Dengue antiviral development and immunopathogenesis

  1. Coronel-Ruiz C, Gutiérrez-Barbosa H, Medina-Moreno S, Velindia-Romero ML, Chua JV, Castellaños JE, Zapata JC. Humanized mice in Dengue research: a comparison with other mouse models. Vaccines. 2020 Jan 22. 8(1). Pii: E39. Doi: 10.3390/vaccines8010039. PubMed PMID: 31979145.
  2. Gutierrez-Barbosa H, Medina-Moreno S, Zapata JC, Chua JV. Dengue infections in Colombia: epidemiological trends of a hyperendemic country. Trop Med Infect Dis. 2020 Oct 3; 5(4): E156. doi:10.3390/tropicalmed5040156. ePub October 3, 2020. PubMed PMID: 33022908.
  3. Gutierrez-Barbosa H, Medina-Moreno S, Davis H, Bryant J, Chua JV, Zapata JC. Humanized Mice for the Study of Dengue Disease Pathogenesis: Biological Assays. In: Borges R (eds) Dengue Virus. Methods in Mol Biol. 2022; 2409: 271-289. Humana, New York. doi: 10.1007/978-1-0716-1879-0_19. PubMed PMID: 34709649.
  4. Obi JO, Gutiérrez-Barbosa H, Chua JV, Deredge DJ. Current Trends and Limitations in Dengue Antiviral Research. Trop Med Infect Dis. 2021 Sep 30; 6(4):180 doi:20.3390/ tropicalmed6040180. PMID: 34698303.

HIV vaccine development

  1. Chua JV, Davis C, Husson JS, Nelson A, Prado I, Flinko R, Lam LWJ, Mutumbi L, Mayer BT, Dong D, Fulp W, Mahoney C, Gerber M, Gottardo R, Gilliam BL, Greene K, Gao H, Yates N, Ferrari G, Tomaras G, Montefiori D, Schwartz JA, Fouts T, DeVico AL, Lewis GK, Gallo RC, Sajadi MM. Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. 2021 Jun 4. doi: 10.1016/j.vaccine.2021.05.090. PubMed PMID: 34099328.
  2. Stafford KA, Mayer B, Fulp W, Chua JV, Davis C, Gilliam B, Dong D, Sajadi MS. Variability of CD4+ cell counts in HIV-1 uninfected volunteers who are eligible for a Phase I HIV vaccine study. J Acquir Immune Defic Syndr. 2020 May 1; 84(1):37-44. Doi:10.1097/QAI. PubMed PMID: 31985697.

Viral hepatitis immunology and therapeutics

  1. Chua JV, Ntem-Mensah A, Abutaleb A, Husson J, Mutumbi L, Lam KW, Ghosh A, Romani S, Poonia B, Lee S, Pascual ML, Frumkin LR, Kottilil S. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study. J Med Virol. 2021. 93(6):3752-3760. doi: 10.1002/jmv.26652. Epub 2020 Nov 5. PubMed PMID: 33150966.
  2. Jakharia N, Kottilil S, Chua JV. Quantification of Hepatitis B surface antigen: Is there a role in HIV-HBV coinfection? AIDS Review. 2019 Oct 3; 21(4):175-183. doi:10.24875/ AIDSRev.19000077. PubMed PMID: 31588136.
  3. Khaman A, Chua JV, Kottilil S. Immunopathology of chronic hepatitis B infection: Role of innate and adaptive immune response in disease progression. Int J Mol Sci. 2021 May 23; 22(11):5497. doi: 10.3390/igms22115497. PubMed PMID: 34071064.

SARS-CoV-2 clinical trials

  1. Narayanan S, Chua JV, Heil E. COVID-19: Pitfalls in offering research participation as therapy in clinical settings. J Gen Intern Med. 2020 Sep 3;1-2. doi:10.1007/s11606.020. 06158.6. PubMed PMID: 32885370.
  2. Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Oct 28; 21(1):897. doi: 10.1186/s13063-020-04819-9. PubMed PMID: 33115543.
  3. Narayanan S, Kottilil S, Chua JV. Review of “Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals.” Rapid Reviews COVID-19. ePub on April 15, 2021.
  4. Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease. Clin Infect Dis. Accepted August 18, 2021.





Additional Publication Citations


  1. Lyke KE, Chua JV, McArthur M, Pa’ahana-Brown F, Strauss KA, Gromowski GD, De La Barrera RA, Froude JW, Pollett S, Jarmen RG, Edelman R, Koren MA. A Phase 1 Open-Label Trial with Dengue-1-Virus Live Virus Human Challenge Assessment of Healthy U.S. Adults Previously Primed with Tetravalent Dengue Virus Purified Inactivated Vaccine and Boosted with Tetravalent Dengue Virus Live Attenuated Vaccine Formulation. American Society for Tropical Medicine and Hygiene, 2021 Annual Meeting. Oral Presentation. Abstract # 1289. November 20, 2021.


Research Interests

Developing novel antiviral for the treatment of neglected and emerging viruses of global importance with special interest in Dengue infection and viral hepatitis B.

Developing dengue human challenge model for the evaluation of vaccines and therapeutics as well as in search of immune correlates of protection against this virus.

Clinical Specialty Details

Surgical Infectious Disease, Hepatitis B and C, HIV medicine

Awards and Affiliations

Honors and Awards

  • 1996    Phi Sigma Biological Honor Society Award for Excellence in the Biological Sciences, University of Philippines, Manila, Philippines. 
  • 1997    Camara-Basa Award for Excellence in Biochemistry, University of Philippines.
  • 2008    Pamela Kisluk Spirit Award, University of Connecticut Health Center.
  • 2017    Faculty Teacher of the Year Award, Division of Infectious Diseases. Department of Medicine. University of Maryland School of Medicine.